Mixed Data for AstraZeneca PLC (JOBS) and Bristol-Myers Squibb Company (JOBS) Diabetes Drug in New Phase III Study

Bookmark and Share

LONDON, Oct 21 (Reuters) - An experimental diabetes drug from AstraZeneca (AZN.L) and Bristol-Myers Squibb (BMY.N) has delivered mixed results in a second late-stage clinical study, by reducing blood sugar levels but also raising infection rates.

Back to news